Analytical Data
-
Gene name
COL6A3
- Application
-
Alternative Names
COL6A3；Collagen alpha-3(VI) chain
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P12111
-
Expression Region
3101-3177aa
-
AA Sequence
TEPLALTETD ICKLPKDEGT CRDFILKWYY DPNTKSCARF WYGGCGGNEN KFGSQKECEK VCAPVLAKPG VISVMGT
-
Molecular Weight
11 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
COL6A3, a member of the collagen VI family, plays a crucial role in maintaining the structural integrity and function of various tissues, particularly in connective tissues. It is primarily expressed in the extracellular matrix (ECM), where it contributes to cell adhesion, proliferation, and differentiation. Abnormalities in COL6A3 expression or mutations in the COL6A3 gene have been associated with several muscular and connective tissue disorders, including Ullrich congenital muscular dystrophy and Bethlem myopathy. These conditions are characterized by muscle weakness and joint contractures, highlighting the importance of COL6A3 in muscle and connective tissue function. To further understand its biological role and potential therapeutic applications, researchers are increasingly focusing on the production and characterization of recombinant COL6A3 protein. This involves using recombinant DNA technology to express COL6A3 in suitable host cells, allowing for the study of its biochemical properties, structure-function relationships, and interactions with other ECM components. Additionally, recombinant COL6A3 can facilitate the development of in vitro models to test therapeutic interventions and improve our understanding of associated pathologies. Overall, the study of COL6A3 recombinant protein offers promising avenues for advancing knowledge in muscle biology and developing potential treatments for connective tissue disorders.
